New Trametinib and Palbociclib Combo Drug for Melanoma Being Studied

New Trametinib and Palbociclib Combo Drug for Melanoma Being Studied

Pfizer and GlaxoSmithKline Combat Melanoma

New Trametinib and Palbociclib Combo Drug for Melanoma Being Studied

An announcement was made by pharmaceutical giants Pfizer and GlaxoSmithKline at the end of November 2013 regarding their agreement to combine efforts in researching a novel melanoma treatment. The clinical study the two companies have commenced involves adult patients with unresectable, metastatic melanoma. This partnership will be a Phase I/II trial designed to determine the effects of Pfizer’s investigational treatment, Palbociclib when added to GlaxoSmithKline’s Trametinib. The MEK inhibitor Trametinib is currently on the market as the brand name Mekinist, as it was approved in early 2013 for the treatment of advanced melanoma.  As an oral inhibitor of both CDK 4 and CDK 6, Palbociclib has already been granted breakthrough status by the FDA in April of 2013, as a treatment for metastatic breast cancer. Both pharmaceutical companies are eager to evaluate the potential anticancer therapy that the combination of these two formidable products renders.

The combination study evaluating Trametinib and Palbociclib is open-label and seeking to determine the best recommended combination regimen of both drugs. As a dose escalation study, this trial of Trametinib and Palbociclib will also evaluate the effects of this dynamic duo of melanoma drugs regarding safety, tumor biomarkers and anti-cancer activity in specific patient populations. These specific groups of patients with metastatic melanoma include people with the BRAF V600 wild type melanoma, as well as those patients with NRAS mutations.

A startling 1 in 50 Americans has a lifetime risk of developing melanoma. Young adult women have experienced a surge in cases-over 50 percent since 1980. Additionally, the American Cancer Society estimates that roughly 77,000 Americans will be diagnosed with melanoma this year, and 9,500 of these patients will not survive. Research and development of medications to treat this growing patient population is necessary and urgent. LGM Pharma provides the APIs Trametinib CAS# 871700-17-3 and Palbociclib CAS# 571190-30-2 for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service